🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ismael A. Vergara

The University of Sydney

ORCID: 0000-0002-2960-2967

Also affiliated with Melanoma Institute Australia

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110
Top 100%
0DataRank
Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Papers

Driven by 6 papers — median percentile 0. Top paper: “Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases”.

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2581
N/A
0.636DataRank · unranked
17 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance

JCO Precision Oncology(2024)10.1200/po-24-00375
N/A
0.327DataRank · unranked
6 citations

Sharon N. Edmiston, Amanda M. Vondras, Allison Reiner, David L. Corcoran, Ronglai Shen +70 more

OrthoCluster

Proceedings of the 11th international conference on Extending database technology Advances in database technology - EDBT '08(2008)10.1145/1352431.1352511
N/A
0.271DataRank · unranked
2 citations

Matthew J. Nesbitt, Jian Pei, Ke Wang, Ismael A. Vergara, Nansheng Chen +1 more

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Nature Communications(2021)10.1038/s41467-021-21207-2
N/A
0DataRank · unranked
70 citations

Dominique‐Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan +21 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110
Top 100%
0DataRank
Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110.v1
Top 100%
0DataRank
Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more